Minireview: Animal Models and Mechanisms of Ovarian Cancer Development

Overview

Journal Endocrinology

Publisher Oxford University Press

Specialty Endocrinology

Date 2012 Mar 8

PMID 22396450

Citations 31

Authors

Lisa K Mullany

JoAnne S Richards

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer in women is a complex and deadly disease, where the molecular events that initiate and control tumor formation remain poorly defined. Therefore, mouse models provide one approach for determining the mechanisms by which specific oncogenic factors cause ovarian surface epithelial cell and granulosa cell transformation. This minireview summarizes the phenotypes of current mouse models that have been generated and some of the underlying mechanisms they have provided.

Citing Articles

Assessing the roles of collagen fiber morphology and matrix stiffness on ovarian cancer cell migration dynamics using multiphoton fabricated orthogonal image-based models.

Alkmin S, Patankar M, Campagnola P Acta Biomater. 2022; 153:342-354.

PMID: 36152908 PMC: 10324295. DOI: 10.1016/j.actbio.2022.09.037.

Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials.

Mendoza-Martinez A, Loessner D, Mata A, Azevedo H Cancers (Basel). 2021; 13(22).

PMID: 34830897 PMC: 8616551. DOI: 10.3390/cancers13225745.

The hallmarks of ovarian cancer: proliferation and cell growth.

Lopez-Reig R, Lopez-Guerrero J EJC Suppl. 2020; 15:27-37.

PMID: 33240440 PMC: 7573473. DOI: 10.1016/j.ejcsup.2019.12.001.

Role of Collagen Fiber Morphology on Ovarian Cancer Cell Migration Using Image-Based Models of the Extracellular Matrix.

Alkmin S, Brodziski R, Simon H, Hinton D, Goldsmith R, Patankar M Cancers (Basel). 2020; 12(6).

PMID: 32481580 PMC: 7352517. DOI: 10.3390/cancers12061390.

Migration dynamics of ovarian epithelial cells on micro-fabricated image-based models of normal and malignant stroma.

Alkmin S, Brodziski R, Simon H, Hinton D, Goldsmith R, Patankar M Acta Biomater. 2019; 100:92-104.

PMID: 31568876 PMC: 6936213. DOI: 10.1016/j.actbio.2019.09.037.

References

Miyoshi I, Takahashi K, Kon Y, Okamura T, Mototani Y, Araki Y . Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation. Mol Reprod Dev. 2002; 63(2):168-76. DOI: 10.1002/mrd.10175. View

Ahmed A, Etemadmoghadam D, Temple J, Lynch A, Riad M, Sharma R . Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010; 221(1):49-56. PMC: 3262968. DOI: 10.1002/path.2696. View

Cho K, Shih I . Ovarian cancer. Annu Rev Pathol. 2008; 4:287-313. PMC: 2679364. DOI: 10.1146/annurev.pathol.4.110807.092246. View

Boyer A, Paquet M, Lague M, Hermo L, Boerboom D . Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis. Carcinogenesis. 2009; 30(5):869-78. PMC: 2675650. DOI: 10.1093/carcin/bgp051. View

Fleming N, Knower K, Lazarus K, Fuller P, Simpson E, Clyne C . Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS One. 2010; 5(12):e14389. PMC: 3004790. DOI: 10.1371/journal.pone.0014389. View

Romero I, Bast Jr R . Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012; 153(4):1593-602. PMC: 3320264. DOI: 10.1210/en.2011-2123. View

Hwang C, Matoso A, Corney D, Flesken-Nikitin A, Korner S, Wang W . Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A. 2011; 108(34):14240-5. PMC: 3161601. DOI: 10.1073/pnas.1017536108. View

Feldser D, Kostova K, Winslow M, Taylor S, Cashman C, Whittaker C . Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010; 468(7323):572-5. PMC: 3003305. DOI: 10.1038/nature09535. View

Auersperg N . The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol. 2010; 30(1):12-21. DOI: 10.1097/PGP.0b013e3181f45f3e. View

10.

Kim J, Coffey D, Creighton C, Yu Z, Hawkins S, Matzuk M . High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012; 109(10):3921-6. PMC: 3309733. DOI: 10.1073/pnas.1117135109. View

11.

Lague M, Paquet M, Fan H, Kaartinen M, Chu S, Jamin S . Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis. 2008; 29(11):2062-72. PMC: 2577137. DOI: 10.1093/carcin/bgn186. View

12.

Trevino L, Giles J, Wang W, Urick M, Johnson P . Gene expression profiling reveals differentially expressed genes in ovarian cancer of the hen: support for oviductal origin?. Horm Cancer. 2011; 1(4):177-86. PMC: 10358175. DOI: 10.1007/s12672-010-0024-8. View

13.

Richards J, Fan H, Liu Z, Tsoi M, Lague M, Boyer A . Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene. 2011; 31(12):1504-20. PMC: 3223552. DOI: 10.1038/onc.2011.341. View

14.

Clark-Knowles K, Senterman M, Collins O, Vanderhyden B . Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One. 2010; 4(12):e8534. PMC: 2795167. DOI: 10.1371/journal.pone.0008534. View

15.

Wong K, Tsang Y, Deavers M, C Mok S, Zu Z, Sun C . BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010; 177(4):1611-7. PMC: 2947258. DOI: 10.2353/ajpath.2010.100212. View

16.

Mullany L, Fan H, Liu Z, White L, Marshall A, Gunaratne P . Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene. 2011; 30(32):3522-36. PMC: 3139785. DOI: 10.1038/onc.2011.70. View

17.

Connolly D, Bao R, Nikitin A, Stephens K, Poole T, Hua X . Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003; 63(6):1389-97. View

18.

Wang Y, Suh Y, Fuller M, Jackson J, Xiong S, Terzian T . Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011; 121(3):893-904. PMC: 3049366. DOI: 10.1172/JCI44504. View

19.

Mullany L, Liu Z, King E, Wong K, Richards J . Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Endocrinology. 2012; 153(4):1638-48. PMC: 3320246. DOI: 10.1210/en.2011-2131. View

20.

Middlebrook B, Eldin K, Li X, Shivasankaran S, Pangas S . Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors. Endocrinology. 2009; 150(12):5208-17. PMC: 2819741. DOI: 10.1210/en.2009-0644. View